3 completed, 2 active not recruiting. 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Adult T Acute Lymphoblastic Leukemia: new trials by email Literature Review of Adult T Acute Lymphoblastic Leukemia trials Research Report on Adult T Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Bortezomib, Cyclophosphamide, Cytarabine - Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 847 | 2014-10-04 | 2026-10-21 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 66 | 2010-06-04 | 2025-11-20 |
| Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 97 | 2009-09-01 | 2026-10-22 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5) · Burkitt Lymphoma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Hodgkin Disease (2) · Immunoblastic Lymphadenopathy (2) · Intraocular Lymphoma (2) · Leukemia, Hairy Cell (2) · Leukemia, Large Granular Lymphocytic (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · DNA Virus Infections (4) · Epstein-Barr Virus Infections (4) · Herpesviridae Infections (4) · Infections (4) · Lymphoma (4)
Calcium Dobesilate (2) · Cyclophosphamide (2) · Cytarabine (2) · Dasatinib (2) · Dexamethasone (2) · Doxorubicin (2) · Etoposide (2) · Leucovorin (2) · Methotrexate (2) · Vincristine (2) · auricularum (2) · dexamethasone 21-phosphate (2) · dexamethasone acetate (2) · merphos (2) · Bortezomib (1)
National Cancer Institute (NCI) (5)
United States (5) · Australia (1) · Canada (1) · New Zealand (1)
David T Teachey (1) · Farhad Ravandi-Kashani (1) · Ivana Gojo (1) · John Sarantopoulos (1) · Tanya Siddiqi (1)
PMID 29618479, PMID 31617432, PMID 35271306, PMID 36603187, PMID 38457359
U10CA032102 (2), U10CA180888 (2), N01CM00071 (1), N01CM62201 (1), N01CM62209 (1), P30CA006973 (1), P30CA033572 (1), U01CA062487 (1), U01CA062502 (1), U01CA062505 (1), U01CA070095 (1), U10CA098543 (1), U10CA180886 (1), UM1CA186691 (1), UM1CA186717 (1)